Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist.

Compton BJ, Farrand KJ, Tang CW, Osmond TL, Speir M, Authier-Hall A, Wang J, Ferguson PM, Chan STS, Anderson RJ, Cooney TR, Hayman CM, Williams GM, Brimble MA, Brooks CR, Yong LK, Metelitsa LS, Zajonc DM, Godfrey DI, Gasser O, Weinkove R, Painter GF, Hermans IF.

Org Biomol Chem. 2019 Jan 31;17(5):1225-1237. doi: 10.1039/c8ob02982b.

PMID:
30656346
2.

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.

Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM.

Cancer Immunol Res. 2019 Mar;7(3):363-375. doi: 10.1158/2326-6066.CIR-18-0572. Epub 2019 Jan 16.

PMID:
30651290
3.

IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy.

Ngai H, Tian G, Courtney AN, Ravari SB, Guo L, Liu B, Jin J, Shen ET, Di Pierro EJ, Metelitsa LS.

J Immunol. 2018 Oct 1;201(7):2141-2153. doi: 10.4049/jimmunol.1800429. Epub 2018 Aug 15.

PMID:
30111631
4.

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM.

Cancer Discov. 2017 Nov;7(11):1238-1247. doi: 10.1158/2159-8290.CD-17-0538. Epub 2017 Aug 22.

5.

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.

Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A.

Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16.

6.

Glycolysis determines dichotomous regulation of T cell subsets in hypoxia.

Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, Yustein JT, Neilson JR, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2678-88. doi: 10.1172/JCI85834. Epub 2016 Jun 13.

7.

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.

Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, Guo L, Xu X, Torikai H, Mo Q, Dotti G, Cooper LJ, Metelitsa LS.

J Clin Invest. 2016 Jun 1;126(6):2341-55. doi: 10.1172/JCI83476. Epub 2016 May 16.

8.

G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM.

Cancer Res. 2015 Jun 15;75(12):2566-79. doi: 10.1158/0008-5472.CAN-14-2946. Epub 2015 Apr 23.

9.

Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.

Xu X, Hegazy WA, Guo L, Gao X, Courtney AN, Kurbanov S, Liu D, Tian G, Manuel ER, Diamond DJ, Hensel M, Metelitsa LS.

Cancer Res. 2014 Nov 1;74(21):6260-70. doi: 10.1158/0008-5472.CAN-14-1169. Epub 2014 Sep 11.

10.

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS.

Blood. 2014 Oct 30;124(18):2824-33. doi: 10.1182/blood-2013-11-541235. Epub 2014 Jul 21.

11.

Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.

Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, Tian G, Margol A, Ahmed N, Asgharzadeh S, Metelitsa LS.

Clin Immunol. 2013 Oct;149(1):55-64. doi: 10.1016/j.clim.2013.06.005. Epub 2013 Jun 18.

12.

G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, Stowers PN, Courtney AN, Lakoma A, Barbieri E, Metelitsa LS, Gunaratne P, Kim ES, Shohet JM.

Cancer Res. 2013 Jul 1;73(13):4134-46. doi: 10.1158/0008-5472.CAN-12-4056. Epub 2013 May 16.

13.

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC.

J Clin Oncol. 2012 Oct 1;30(28):3525-32. Epub 2012 Aug 27.

14.

C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes.

Liu Z, Courtney AN, Metelitsa LS, Bittman R.

Chembiochem. 2012 Aug 13;13(12):1733-7. doi: 10.1002/cbic.201200374. Epub 2012 Jul 10. No abstract available.

15.

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.

Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS.

J Clin Invest. 2012 Jun;122(6):2221-33. doi: 10.1172/JCI59535. Epub 2012 May 8.

16.

Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment.

Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N.

PLoS One. 2011;6(5):e20267. doi: 10.1371/journal.pone.0020267. Epub 2011 May 27.

17.

Selective gene transfection of individual cells in vitro with plasmonic nanobubbles.

Lukianova-Hleb EY, Samaniego AP, Wen J, Metelitsa LS, Chang CC, Lapotko DO.

J Control Release. 2011 Jun 10;152(2):286-93. doi: 10.1016/j.jconrel.2011.02.006. Epub 2011 Feb 17.

18.

Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Metelitsa LS.

Clin Immunol. 2011 Aug;140(2):119-29. doi: 10.1016/j.clim.2010.10.005. Epub 2010 Nov 20. Review.

19.

Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.

Xiong G, Husseiny MI, Song L, Erdreich-Epstein A, Shackleford GM, Seeger RC, J├Ąckel D, Hensel M, Metelitsa LS.

Int J Cancer. 2010 Jun 1;126(11):2622-34. doi: 10.1002/ijc.24957.

20.

Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.

Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS.

J Clin Invest. 2009 Jun;119(6):1524-36. doi: 10.1172/JCI37869.

21.

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.

Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA.

Cancer Res. 2009 Jan 1;69(1):329-37. doi: 10.1158/0008-5472.CAN-08-0613.

22.

Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS.

J Clin Invest. 2007 Sep;117(9):2702-12.

23.
24.

Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans.

Baev DV, Peng XH, Song L, Barnhart JR, Crooks GM, Weinberg KI, Metelitsa LS.

Blood. 2004 Dec 15;104(13):4150-6. Epub 2004 Aug 24.

25.

Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2.

Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC.

J Exp Med. 2004 May 3;199(9):1213-21.

26.

Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells.

Metelitsa LS.

Clin Immunol. 2004 Mar;110(3):267-76. Review.

PMID:
15047204
27.

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC.

Leukemia. 2003 Jun;17(6):1068-77.

PMID:
12764370
28.

NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production.

Loza MJ, Metelitsa LS, Perussia B.

Eur J Immunol. 2002 Dec;32(12):3453-62.

30.

Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.

Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC.

J Immunol. 2001 Sep 15;167(6):3114-22.

31.

Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.

Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL.

Cancer Res. 2000 Feb 1;60(3):712-21.

32.

Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.

Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP.

J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46.

PMID:
10393722

Supplemental Content

Loading ...
Support Center